NovoCure Ltd(NVCR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.31 | Insider Own | 10.11% | Shs Outstand | 116.4M | Perf Week | -13.18% |
| Market Cap | 1.53B | Forward P/E | - | EPS next Y | 36.1% | Insider Trans | -0.46% | Shs Float | 104.7M | Perf Month | -17.81% |
| Enterprise Value | 1.31B | PEG | - | EPS next Q | -0.22 | Inst Own | 90.63% | Short Float | 12.25% | Perf Quarter | -11.66% |
| Income | -0.15B | P/S | 2.18 | EPS this Y | 8.84% | Inst Trans | 4.43% | Short Ratio | 9.43 | Perf Half Y | -13.81% |
| Sales | 0.70B | P/B | 4.52 | EPS next 5Y | 42.3% | ROA | -14.56% | Short Interest | 12.82M | Perf YTD | 1.39% |
| Book/sh | 2.9 | P/C | 3.39 | EPS past 3/5Y | -11.4% - | ROE | -43.22% | 52W High | -38.88% ($21.45) | Perf Year | -2.74% |
| Cash/sh | 3.87 | P/FCF | - | Sales past 3/5Y | 6.81% 5.8% | ROIC | -26% | 52W Low | 33.5% ($9.82) | Perf 3Y | 3.72% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 16.12% | Gross Margin | 76.13% | Volatility(W/M) | 7% 5.41% | Perf 5Y | -87.22% |
| Dividend TTM | - | EV/Sales | 1.87 | Sales Y/Y TTM | 10.95% | Oper. Margin | -22.08% | ATR (14) | 0.81 | Perf 10Y | 114.22% |
| Dividend Ex-Date | - | Quick Ratio | 2.7 | EPS Q/Q | 62.48% | Profit Margin | -21.25% | RSI (14) | 33.59 | Recom | 1.86 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.89 | Sales Q/Q | 15.6% | SMA20 | -10.26% ($14.61) | Beta | 1.07 | Target Price | $25.71 |
| Payout | - | Debt/Eq | 0.69 | Earnings | 2026/10/29 | SMA50 | -17.45% ($15.88) | Rel Volume | 4.38 | Prev Close | $14.17 |
| Employees | 1605 | LT Debt/Eq | 0.69 | EPS/Sales Surpr. | 61.69% 6.1% | SMA200 | -11.53% ($14.82) | Avg Volume(3M) | 1.36M | Price | $13.11 |
| IPO | 2015/10/2 | Option/Short | Yes/Yes | Trades | 30894 | Volume | 5,956,050 | Change | -7.48% |
🧠 This is a medical device company that develops and commercializes cancer treatment devices using tumor-treating electric field technology. The company treats cancers such as brain tumors with devices that disrupt cancer cell division using electric fields, and is expanding indications to other cancer types, including lung cancer. It is a tumor-treatment device company featuring a differentiated, drug-free, electric field-based approach to cancer therapy.
Over the past 1 year, roughly in the middle
39% below its 1-year high.
Traded more than usual. That is 438% of its average volume.
NVCR has a sound balance sheet but weak earning power
Of every $100 in sales, $22.08 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +8.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $218. Peers typically go for $345.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -87.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 90.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #33 of 142 in the industry
Based on market cap of $2B.
FAQ
What kind of company is NVCR?
NVCR belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of NVCR?
The market cap of NVCR is approximately $1.5B, ranking 2,291 within its sector.
What is the 52-week high and low for NVCR?
NVCR has recorded a 52-week high of $21.45 and a low of $9.82.
